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Patients with an implantable cardioverter-de~brillator
(ICD) may receive frequent shocks or antitachycardia
pacing for monomorphic ventricular tachycardia
(MVT) despite suppressive drug therapy. Antitachy-
cardia pacing is often well-tolerated but not always
effective. High voltage cardioversion is usually painful
and may cause severe, disabling anxiety for some pa-
tients. Therefore, catheter ablation is an important ad-
junct to medical therapy in patients with coronary ar-
tery disease (CAD) who have frequent shocks for
episodes of MVT. In 56–100% of selected patients,
hemodynamically-tolerated MVT can be successfully
ablated with radiofrequency energy [1,2,3,4,5,6].
Herein we review the indications, bene~ts and risks of
radiofrequency ablation of MVT in patients with CAD
and an ICD.
Willems et al. [4] published the ~rst series of pa-
tients with catheter ablation of MVT as an adjunct to
ICD therapy. Among 6 patients, 5 had MVT originating
in a healed myocardial scar related to CAD and the
other patient had bundle branch reentry. Four of 6
patients had incessant MVT at the time of the proce-
dure and the remaining 2 had frequent ICD shocks.
The MVT in all patients was successfully ablated, but
2 of 6 patients continued to had relatively frequent
ICD shocks during the follow-up period.
Radiofrequency ablation of MVT decreases ICD
shocks and improves quality of life, as shown in a pro-
spective study of 21 consecutive patients with CAD
and a previous myocardial infarction [6]. Their mean
ejection fraction was 22% and they had failed an aver-
age of  2.5 suppressive  drugs; 16 of 21 were taking
amiodarone at the time of the ablation procedure and
18 of 21 were on multiple antiarrhythmic drugs. An-
tiarrhythmic medications were continued through the
procedure and inde~nitely thereafter. The patients had
received an average of 17 shocks for MVT in the month
before ablation and one patient had received 54 shocks.
Fourteen of 21 patients had their spontaneous MVT(s)
recorded on a 12-lead ECG and the MVT cycle length
was available in the remainder of patients by stored
electrogram analysis from the ICD. An induced MVT
was presumed to be clinically-important if it matched
the morphology and cycle length recorded on a 12-lead
ECG or the cycle length alone in those patients without
12-lead ECG documentation. Twenty-six MVT’s in 21
patients were felt to be responsible for clinical symp-
toms  prior  to the  ablation procedure. A total  of 85
MVT’s (range 1 to 15 per patient) were inducible with
a mean cycle length of 430 ms. Twenty additional induc-
ible MVT’s were targeted for ablation besides the 26
MVT’s felt to be responsible for the majority of clinical
symptoms. The remaining 39 MVT’s were poorly toler-
ated and could not be mapped.
The patients underwent an average of 1.4 proce-
dures and 12 radiofrequency energy applications. The
procedures lasted on average 93 minutes from the on-
set of mapping to the last radiofrequency application
and averaged 50 minutes of _uoroscopy time. The map-
ping techniques have been previously described and do
not require sophisticated recording systems [7,8]. Con-
cealed entrainment was the most useful criterion for a
successful radiofrequency application. Thirty-six of 46
targeted MVT’s (78%) were successfully ablated. If the
MVT was well-tolerated, the success rate was 89%.
Sixteen of 21 patients had a successful procedure as
de~ned by elimination of the clinically-important MVT
(76%). A signi~cant complication occurred in only one
patient who required a dual chamber pacemaker after
a successful ablation of a high septal MVT. The average
number of ICD therapies per month for patients fol-
lowed for an average of 1 year (range 1 to 32 months)
was signi~cantly decreased in the 16 patients who un-
derwent a successful ablation procedure (59 6 80 vs 0.5
6 1, p50.01). Among the patients with unsuccessful
procedures, the difference in monthly ICD therapies
did not reach statistical signi~cance (358 6 661 vs 1.5
6 2, p50.3). There were no predictors of a successful
ablation. A quality-of-life questionnaire  was distrib-
uted to all patients within 1 month of the last follow-up
date. This score signi~cantly improved in patients with
a successful procedure but not in patients with a failed
ablation.
The bene~ts of catheter ablation as an adjunct to
ICD therapy in patients with hemodynamically-toler-
ated MVT are clear from the results of Strickberger
et.al. [6]. Patients with successful ablation had fewer
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ICD therapies and an improved quality of life. These
patients were carefully selected, however, to avoid the
pitfalls of attempting to ablate MVT that is hemody-
namically poorly-tolerated. Mapping the MVT circuit
requires hemodynamic stability for sustained periods
while the catheter is manipulated to potential ablation
sites. Mapping in sinus rhythm has not proven to be
effective because, although the boundaries of a myo-
cardial scar can be identi~ed in sinus rhythm by frag-
mented, low amplitude  electrograms, the volume of
tissue critical to maintaining a reentrant circuit is small
relative to the volume of scar tissue. Newer mapping
technology, such as noncontact [9] or basket electrodes
[10], may allow ablation of hemodynamically-unstable
ventricular tachycardia by identifying a critical compo-
nent of the  reentrant circuit during a few beats of
ventricular tachycardia. Larger lesion size with future
catheter technologies may also abrogate the need for
precise mapping, although the effects of large lesions
on myocardial function need to be examined. Given the
current technology and experience, one should con-
sider catheter ablation in patients whose MVT is felt to
be hemodynamically stable. In general, these patients
have a tachycardia cycle length .300ms and/or an ab-
sence of symptoms to suggest profound hypotension,
for example syncope.
There are signi~cant risks associated with catheter
ablation of MVT in patients with CAD. In the Strick-
berger series [6] no patients died as a direct result of
the ablation, and the sole complication was heart block
requiring a dual chamber pacemaker. An earlier report
of 15 patients from the University of Michigan re-
ported no deaths and no signi~cant complications [1].
The mortality rate in other published reports may be
as high as 2% and other reported complications include
cardiac perforation and tamponade, stroke, myocardial
infarction, and femoral artery occlusion [3,5]. The tech-
nique most successful in identifying a critical portion of
the MVT circuit is concealed entrainment. The positive
predictive value of a successful ablation is improved if
concealed entrainment is accompanied by a stimulus-
QRS interval/ventricular tachycardia cycle length ra-
tio of #70%, a match of the stimulus-QRS and electro-
gram-QRS intervals, or isolated mid-diastolic
potentials that  cannot be  dissociated from the  ven-
tricular tachycardia [8]. Post-pacing interval has also
been shown to be effective [2]. Endocardial activation
time distinct from isolated diastolic potentials and
pace-mapping is generally of little additional bene~t to
the criteria mentioned above [8]. More than one mor-
phology of MVT can frequently be induced in patients
with CAD [1,3,6,7,11]. Although it is important to tar-
get the  MVT which has been documented to  occur
spontaneously, other hemodynamically stable, induced
MVT’s are probably important to ablate since they may
occur clinically [11]. However, this has not been sys-
tematically studied.
There is no information in the literature to guide
antiarrhythmic drug use following successful catheter
ablation of MVT. In patients who underwent an acutely
successful ablation in the University of Michigan series
[6], very few shocks were experienced during the fol-
low-up period. All of these patients, however, contin-
ued their antiarrhythmic drugs during follow-up. Until
further evidence is available, patients who are tolerant
of appropriate antiarrhythmic drug therapy should
continue drug therapy following an acutely successful
procedure. Although not statistically signi~cant, some
patients also seemed to bene~t despite an acute abla-
tion failure. These patients had antiarrhythmic drugs
modi~ed, but it is possible that the myocardial sub-
strate was favorably altered such that antiarrhythmic
drug therapy was more ef~cacious.
In conclusion, radiofrequency catheter ablation of
hemodynamically-stable MVT is an important adjunct
to but not replacement for medical therapy in care-
fully selected patients with coronary artery disease
and an implantable cardioverter-de~brillator (Table
1). The success rate is approximately 75% in experi-
enced hands and is associated with a low complication
rate, fewer ICD therapies and an improved quality-
of-life.
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